W. Kalow

14.2k total citations · 2 hit papers
237 papers, 11.1k citations indexed

About

W. Kalow is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, W. Kalow has authored 237 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pharmacology, 53 papers in Molecular Biology and 46 papers in Pharmacology. Recurrent topics in W. Kalow's work include Pharmacogenetics and Drug Metabolism (70 papers), Metabolism and Genetic Disorders (29 papers) and Cholinesterase and Neurodegenerative Diseases (24 papers). W. Kalow is often cited by papers focused on Pharmacogenetics and Drug Metabolism (70 papers), Metabolism and Genetic Disorders (29 papers) and Cholinesterase and Neurodegenerative Diseases (24 papers). W. Kalow collaborates with scholars based in Canada, United States and Germany. W. Kalow's co-authors include T. Inaba, Bing-Kou Tang, Beverley A. Britt, K. Genest, Bing Tang, Frank J. Gonzalez, S V Otton, László Endrényi, Vural Özdemir and David J. Stewart and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

W. Kalow

227 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver

1989 434 citations T. Inaba, W. Kalow et al. profile →
A METHOD FOR THE DETECTION OF ATYPICAL FORMS OF HUMAN SERUM CHOLINESTERASE. DETERMINATION OF DIBUCAINE NUMBERS

1957 386 citations W. Kalow et al. profile →

Peers

Countries citing papers authored by W. Kalow

Since Specialization

Citations

This map shows the geographic impact of W. Kalow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Kalow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Kalow more than expected).

Fields of papers citing papers by W. Kalow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Kalow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Kalow. The network helps show where W. Kalow may publish in the future.

Co-authorship network of co-authors of W. Kalow

This figure shows the co-authorship network connecting the top 25 collaborators of W. Kalow. A scholar is included among the top collaborators of W. Kalow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Kalow. W. Kalow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine 2007 ·Pharmacogenetics and Genomics ·Eleni Aklillu, W. Kalow, László Endrényi, Patricia A. Harper, Jun Miura, Vural Özdemir	30
2	Pharmacogenomics: Historical Perspective and Current Status 2005 ·Pharmacogenomics ·W. Kalow	14
3	Human pharmacogenomics: The development of a science 2004 ·Human Genomics ·W. Kalow	24
4	Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators 2002 ·The Pharmacogenomics Journal ·W. Kalow	4
5	CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia 2001 ·Journal of Clinical Psychopharmacology ·Vural Özdemir, W. Kalow, (unknown), Evan Collins, James L. Kennedy, Bing-Kou Tang, Lawrence J. Albers, Christopher Reist, (unknown), (unknown), Pegah Afra	70
6	Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine 2001 ·European Journal of Clinical Pharmacology ·Sherwin K. B. Sy, Bing-Kou Tang, (unknown), Eve A. Roberts, W. Kalow	10
7	Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E 1 in human liver and in human erythrocytes 1997 ·European Journal of Clinical Pharmacology ·(unknown), (unknown), Boxin Tang, W. Kalow	12
8	Interactions of amphetamine analogs with human liver CYP2D6 1997 ·Biochemical Pharmacology ·Dafang Wu, S. Victoria Otton, T. Inaba, W. Kalow, Edward M. Sellers	134
9	Life of a Pharmacologist or The Rich Life of a Poor Metabolizer 1995 ·Pharmacology & Toxicology ·W. Kalow	5
10	Low CYP1A2 activity in rural Shona children of Zimbabwe* 1995 ·Clinical Pharmacology & Therapeutics ·Collen Masimirembwa, (unknown), Julia A. Hasler, Bing-Kou Tang, W. Kalow	18
11	Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6) 1993 ·European Journal of Clinical Pharmacology ·(unknown), Rita Müller, W. Kalow	4
12	Pharmacogenetics: Past and future 1990 ·Life Sciences ·W. Kalow	33
13	The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. 1990 ·Environmental Health Perspectives ·George H. Lambert, Dale A. Schoeller, Harold E. B. Humphrey, Alvin N. Kotake, (unknown), Monica Campbell, W. Kalow, Stephen P. Spielberg, M. D. Budd	38
14	Haloperidol reduction can be assayed in human red blood cells 1989 ·Canadian Journal of Physiology and Pharmacology ·T. Inaba, W. Kalow, Toshiyuki Someya, S. Takahashi, Siu Wah Cheung, Siu Wa Tang	26
15	Method to determine the enantiomers of ibuprofen from human urine by high-performance liquid chromatography 1988 ·Journal of Chromatography B Biomedical Sciences and Applications ·Deborah A. Nicoll‐Griffith, T. Inaba, B. Tang, W. Kalow	28
16	Ethnic differences in reactions to drugs and xenobiotics : proceedings of a meeting held in Titisee, Black Forest, Federal Republic of Germany, October 3-6, 1985 supported by the Boehringer Ingelheim Fonds 1986 ·W. Kalow, H. W. Goedde, Dharam P. Agarwal	1
17	Metabolism of xenobiotics in different populations 1982 ·Canadian Journal of Physiology and Pharmacology ·W. Kalow	11
18	Antipyrine metabolites in two populations. 1981 ·PubMed ·T. Inaba, Haruto Uchino, D. Kadar, W. Kalow	5
19	N-Hydroxylation of pentobarbital in man. 1977 ·Drug Metabolism and Disposition ·B. Tang, T. Inaba, W. Kalow	13
20	THE RELATION BETWEEN DOSE OF SUCCINYLCHOLINE AND DURATION OF APNEA IN MAN 1957 ·Journal of Pharmacology and Experimental Therapeutics ·W. Kalow, (unknown)	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact